A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples